Niacin and HDL cholesterol - Time to face facts

New England Journal of Medicine

Volumn 371, Issue 3, 2014, Pages 271-273

  Lloyd Jones, Donald M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAROPIPRANT PLUS NICOTINIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID;

ATHEROSCLEROSIS; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EDITORIAL; GASTROINTESTINAL DISEASE; GLYCEMIC CONTROL; HUMAN; HYPERCHOLESTEROLEMIA; INFECTION; INFESTATION; MUSCULOSKELETAL DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; TREATMENT OUTCOME;

ATHEROSCLEROSIS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPOLIPIDEMIC AGENTS; INDOLES; INFECTION; MALE; NIACIN;

EID: 84904262929     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1406410     Document Type: Editorial

References (9)

1. Wilkins JT, Ning H, Stone NJ, et al. Coronary heart disease risks associated with high levels of HDL cholesterol. J Am Heart Assoc 2014;3(2):e000519.
2. Coronary Drug Project. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-81.
3. The HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014;371:203-12.
4. Anderson TJ, Boden WE, Desvigne-Nickens P, et al. Safety profile of extended-release niacin in the AIM-HIGH trial. N Engl J Med 2014;371:288-90.
5. The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-67.
6. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013 November 12 (Epub ahead of print).
7. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22. (Pubitemid 350146106)
8. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012;367:2089-99.
9. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012;380:572-80. [Erratum, Lancet 2012;380:564.]